FATE THERAPEUTICS INC Auditor
The independent registered public accounting firm that signed the audit report in each annual report on Form 10-K, newest first. PCAOB firm ID and the internal-control attestation are as tagged on the cover from fiscal 2021; earlier rows come from the signed report text.
- 2026-02-26: Fiscal year end 2025-12-31; Auditor Ernst & Young, LLP; PCAOB firm ID 42; Location San Diego, California.
- 2025-03-05: Fiscal year end 2024-12-31; Auditor Ernst & Young, LLP; PCAOB firm ID 42; Location San Diego, CA.
- 2024-02-26: Fiscal year end 2023-12-31; Auditor Ernst & Young, LLP; PCAOB firm ID 42; Location San Diego, CA.
- 2023-02-28: Fiscal year end 2022-12-31; Auditor Ernst & Young, LLP; PCAOB firm ID 42; Location San Diego, CA.
| Filed | Fiscal year end | Auditor | PCAOB firm ID | Location | Internal-control attestation |
|---|
| 2026-02-26 | 2025-12-31 | Ernst & Young, LLP | 42 | San Diego, California | No |
|---|
| 2025-03-05 | 2024-12-31 | Ernst & Young, LLP | 42 | San Diego, CA | No |
|---|
| 2024-02-26 | 2023-12-31 | Ernst & Young, LLP | 42 | San Diego, CA | No |
|---|
| 2023-02-28 | 2022-12-31 | Ernst & Young, LLP | 42 | San Diego, CA | Yes |
|---|
| 2022-02-28 | 2021-12-31 | Ernst & Young, LLP | 42 | San Diego, CA | Yes |
|---|
| 2021-02-24 | 2020-12-31 | Ernst & Young, LLP | | San Diego, California | Yes |
|---|
| 2020-03-02 | 2019-12-31 | Ernst & Young, LLP | | San Diego, California | |
|---|
| 2019-03-05 | 2018-12-31 | Ernst & Young LLP | | San Diego, California | |
|---|
| 2018-03-05 | 2017-12-31 | Ernst & Young LLP | | San Diego, California | |
|---|
| 2017-03-16 | 2016-12-31 | Ernst & Young LLP | | San Diego, California | |
|---|
| 2016-03-03 | 2015-12-31 | Ernst & Young LLP | | San Diego, California | |
|---|
| 2015-03-12 | 2014-12-31 | ERNST & YOUNG LLP | | Diego, California | |
|---|
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
|---|
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
|---|
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
|---|
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
|---|
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
|---|
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
|---|
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
|---|
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
|---|
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
|---|